TherapeuticsMD (NASDAQ:TXMD) Trading Down 1.5% – What’s Next?

TherapeuticsMD, Inc. (NASDAQ:TXMD) was down 1.5% during mid-day trading on Wednesday . The stock traded as low as $1.91 and last traded at $1.94. 16,607 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 30,226 shares. The stock had previously closed at $1.97.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of TherapeuticsMD in a report on Thursday, July 2nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

TherapeuticsMD Stock Performance

The company has a 50 day moving average of $2.04 and a 200 day moving average of $2.13. The stock has a market capitalization of $22.45 million, a price-to-earnings ratio of 32.33 and a beta of 0.59.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13. TherapeuticsMD had a return on equity of 0.32% and a net margin of 5.34%.The company had revenue of $0.72 million for the quarter, compared to analyst estimates of $19.77 million.

Hedge Funds Weigh In On TherapeuticsMD

Hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC boosted its position in TherapeuticsMD by 125.5% during the third quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock worth $36,000 after acquiring an additional 19,073 shares during the last quarter. Renaissance Technologies LLC lifted its stake in TherapeuticsMD by 171.8% in the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock worth $157,000 after purchasing an additional 61,000 shares in the last quarter. Finally, Tejara Capital Ltd boosted its holdings in shares of TherapeuticsMD by 1.9% during the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock worth $572,000 after purchasing an additional 6,649 shares during the last quarter. 30.74% of the stock is owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.